Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | PDE5A | O76074 | 11/20 | 0.52 |
| ▸ | PDE6D | O43924 | 2/20 | 0.48 |
| ▸ | PDE6A | P16499 | 2/20 | 0.48 |
| ▸ | PDE6G | P18545 | 2/20 | 0.48 |
| ▸ | PDE6B | P35913 | 2/20 | 0.48 |
| ▸ | PDE6C | P51160 | 2/20 | 0.48 |
| ▸ | PDE6H | Q13956 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28818029 | 0.87 | HTT (0.56) | HTTPDE5A | |
| SCHEMBL31189121 | 0.83 | PDE5A (0.54) | PDE5A | |
| SCHEMBL4974720 | 0.83 | PDE5A (0.54) | PDE5A | |
| SCHEMBL4974488 | 0.83 | HTT (0.46) | HTTPDE5A | |
| SCHEMBL4712339 | 0.82 | HTT (0.76) | HTTPDE5A | |
| SCHEMBL5249215 | 0.82 | PDE5A (0.51) | PDE5A | |
| SCHEMBL5888355 | 0.80 | PDE5A (0.50) | PDE5A | |
| SCHEMBL5888359 | 0.80 | PDE5A (0.46) | HTTPDE5A | |
| SCHEMBL1679801 | 0.80 | PDE5A (0.59) | HTTPDE5APDE6DPDE6APDE6G | |
| SCHEMBL31694381 | 0.80 | PDE5A (0.59) | HTTPDE5APDE6DPDE6APDE6G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| EP-1219609-B1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO (JP) | 2007-04-04 | — | — | EP | disclosed |
| US-7078522-B2 | Pyridopyrimidine or naphthyridine derivative | TANABE SEIYAKU CO., LTD. (JP) | 2006-07-18 | — | — | US | disclosed |
| US-20050101615-A1 | Pyridopyrimidine or naphthyridine derivative | TANABE SEIYAKU CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| US-6797709-B2 | SEXUAL DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20040142930-A1 | Cyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-22 | — | — | US | disclosed |
| US-20030229095-A1 | Sexual disorders | TANABE SEIYAKU CO., LTD. | 2003-12-11 | — | — | US | disclosed |
| US-20030229089-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-11 | — | — | US | disclosed |
| US-6656935-B2 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| EP-1364950-A1 | PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE | TANABE SEIYAKU CO., LTD. (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-1219609-A1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | PDE3A, PDE3B, PDE2A | HTT 3224/4885PDE5A 4/4885PDE6D 55/4885 |
| US-20050101615-A1 | Pyridopyrimidine or naphthyridine derivative | PDE5A, PDE3B, PDE3A | HTT 3687/4885PDE5A 1/4885PDE6D 15/4885 |
| US-20030229095-A1 | Sexual disorders | PDE3B, PDE3A, PDE2A | HTT 3960/4885PDE5A 4/4885PDE6D 12/4885 |
| US-20030229089-A1 | Cyclic compounds | PDE3B, PDE5A, PDE9A | HTT 3412/4885PDE5A 2/4885PDE6D 16/4885 |
| US-20040142930-A1 | Cyclic compounds | PDE3B, PDE4A, PDE5A | HTT 3406/4885PDE5A 3/4885PDE6D 14/4885 |
| US-20080027037-A1 | Cyclic compounds | PDE4A, PDE4B, PDE3B | HTT 3758/4885PDE5A 4/4885PDE6D 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.